secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001528287-24-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q1 revenue $18.1M (+25% YoY), net loss $8.9M; loan maturity extended to Sept 2026
--------------------------------------------------------------------------------

- Revenue $18.1M vs $14.5M in Q1 2023, driven by RNS System and DIXI Medical sales.
- Net loss $8.9M, improved from $10.4M; operating loss $7.5M vs $8.3M.
- Cash burn $7.6M, down from $9.8M; cash & investments $58.9M; debt $58.0M.
- Term loan maturity extended one year to Sept 30, 2026; PIK interest option shortened.
- FY2024 guidance reaffirmed: revenue $73-77M, gross margin 72-74%, opex $80-84M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/0001528287-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/npce-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001528287-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer